R. Schots MD, PhD

P.19 Clonaly related monoclonal B-cell lymphocytosis and diffuse large B-cell lymphoma in a patient treated for EBV-positive Hodgkin lymphoma

P.27 Invariant Natural Killer T cells in the 5T33 multiple myeloma model

P.34 Multiple Myeloma in the era of novel agents: a single center experience

Proteasome inhibitors in multiple myeloma and other haematological malignancies

Summary

The proteasome is an important anticancer target. Bortezomib, as a first-in-class proteasome inhibitor has become a valuable drug in the therapeutic armamentarium against multiple myeloma. This drug-review summarises the current indications for the use of bortezomib in myeloma. In addition, its emerging role as a consolidating / maintenance agent after autologous stem cell transplantation and its use in patients with bad cytogenetical markers or renal impairment is addressed. We also include the available data on the subcutaneous route of administration as an alternative to mitigate peripheral neuropathy. The promising evidence of proteasome inhibitors in other haematological malignancies (low grade lymphomas, mantle cell lymphoma, Waldenström’s disease and systemic amyloidosis) is also summarised.

(BELG J HEMATOL 2012;3:95–104)

Academic clinical trials run by the Transplant Committee of the Belgian Hematological Society

Summary

The Transplantation Committee of the Belgian Hematological Society (BHS) is supported by all university centres and nonuniversity centres with significant transplant activity. The committee is involved in the development of transplant guidelines and recommendations, the transplant peer review process, contacts with regulatory authorities, the introduction of expanded access and medical need programs and the initiation of academic studies addressing important questions in the transplant field. Since 2008, eight clinical trials have been initiated after approval by the Ethics Committees and the National Competent Authority (AFMPS/FAGG). So far, one of them has been completed and is being prepared for publication. In this paper, we briefly describe the rationale, objectives, treatment arms, major inclusion criteria and current status of these different trials. In addition and for each trial a link is provided to the BHS website to obtain more details regarding inclusion criteria, participating centres and administrative/contact information.

(BELG J HEMATOL 2012;3:62–67)